AmeriCann Adds Two Accomplished Members to Its Advisory Board to Assist the Company with National Growth

Appointments Enhance Expertise as the Company Launches New Research Programs

DENVER, CO / ACCESSWIRE / July 29, 2015 / AmeriCann, Inc. (OTCQX: ACAN), a company that designs, develops and owns advanced medical cannabis facilities, announced that it has added two new members to its Advisory Board.

Dr. D. Michael Anderson, a noted epidemiologist and former researcher for the National Institutes of Health, and Eric Forington, a long-time researcher and expert on cannabis genetics, have both joined the AmeriCann Advisory Board.

AmeriCann’s Advisory Board consists of a diverse array of experts from a wide variety of disciplines. These team members collaborate with AmeriCann to provide advanced knowledge and specialized perspectives. The Advisory Board’s objective is to help AmeriCann lead the industry and elevate the quality of medicine delivered to patients.

AmeriCann Chief Executive Officer Tim Keogh stated that, “AmeriCann is a recognized leader in the design and development of state-of-the-art medical marijuana cultivation and processing facilities, with over 1,000,000 square feet of projects in development.”

Keogh added, “The addition of Dr. Anderson and Mr. Forington to our Advisory Board accelerates our knowledge in the area of plant science, genetics and in helping our partners to produce more effective medicines. We have very ambitious programs that we will soon introduce with the valuable input from our new team members.”

Advisory Board members Dr. Anderson stated, “As an epidemiologist and human subjects’ protection specialist, I am very excited to become an Advisor to AmeriCann and to help guide health-related cannabis applications. AmeriCann presents a great opportunity to encourage more clinical trial R&D to increase knowledge and benefit patients.”

Advisory Board member Eric Forington added, “With seemingly limitless potential and a vast multitude of uses, the cannabis plant is one of the most exciting rediscovery’s of our lifetime. AmeriCann has the foresight and the ability to bring cannabis to its full potential and I am excited to be a part of the Advisory Board that will help oversee the progression and implementation of this highly valuable plant.”

The legal regulated cannabis industry has realized explosive growth over the past two years and most experts expect this trend to accelerate. Consensus estimates project legal cannabis will grow from a $2.5 billion industry in 2015 to over $15 billion by 2020.

D. Michael Anderson, Ph.D., MPH

Dr. Anderson has over 25 years’ experience in public health research design and ethics. He has been a leader in the review, funding, and commercialization of behavioral research and development, including tech-based applications for health promotion and disease prevention. He received his Ph.D. and MPH at the University of Minnesota School of Public Health.

Eric Forington

Mr. Forington is the Head of Breeding and Strain Development for 303 Seeds, a cannabis genetics and seed company based in Denver, Colorado. After several years of cannabis R&D focused on the psychoactive cannabinoid compound THC, Mr. Forington shifted his focus to non-psychoactive cannabinoids including CBD, CBG, CBC and CBN. His breeding work includes the highest lab tested cannabidiol (CBD) and cannabigerol (CBG) plant specimens known in the medical cannabis market and he has received several cannabis awards.

About AmeriCann

AmeriCann designs, develops and owns advanced medical cannabis facilities to produce the best possible medical cannabis in most efficient manner utilizing advanced, sustainable practices. The Company has over 1,000,000 square feet of facilities in development. AmeriCann does not cultivate, process or distribute cannabis, but partners with local business to serve marijuana patients in their communities. More information about the Company is available at: https://www.acaninfo.com.

Forward-Looking Statements

Forward-Looking Statements. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” ‘would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K for the year ended September 30, 2014, including but not limited to the discussion under “Risk Factors” therein, which the Company has filed with the SEC and which may be viewed at http://www.sec.gov.

Contact Information

Investors:
Hayden IR
hart@haydenir.com
917-658-7878

Media:
media@ACANinfo.com
303-862-9000

SOURCE: AmeriCann, Inc.

ReleaseID: 430912